Waning Humoral Immune Response Following the Third and Fourth SARS‐COV‐2 Vaccine: A Cohort Study in Healthcare WorkersOriginal Article Published on 2024-08-272024-09-05 Journal: Influenza and Other Respiratory Viruses [Category] update2024, [키워드] Antibody Response booster doses COVID‐19 Healthcare workers Vaccine [DOI] 10.1111/irv.70003 PMC 바로가기 [Article Type] Original Article
Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, SpainArticle Published on 2023-12-302024-09-05 Journal: Vaccines [Category] update2024, [키워드] booster doses COVID-19 HIV SARS-CoV-2 vaccination [DOI] 10.3390/vaccines12010044 PMC 바로가기 [Article Type] Article
COVAD survey 2 long-term outcomes: unmet need and protocolArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 치료제, [키워드] adverse event antiviral drug approach approved Autoimmune diseases baseline booster doses cohorts COVID-19 COVID-19 infection COVID-19 vaccine disease Effect effort groups help Heterologous immune modulation Immunity IMPROVE long-term adverse effects pandemic protocol reduce registries risk syndrome synergistic Tolerability translation unmet need vaccination Vaccine while [DOI] 10.1007/s00296-022-05157-6 PMC 바로가기
Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An updateArticle Published on 2022-11-302023-07-09 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] B.1.1.529 booster doses enhancing immunity Omicron variant protection SARS-CoV-2 Vaccines [DOI] 10.1080/21645515.2022.2065824 PMC 바로가기
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 – United States, January-July 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] African American Alaska Antiviral Antiviral treatment antivirals Asian black booster doses Care COVID-19 COVID-19 in patient COVID-19 patient COVID-19 treatments COVID-19 vaccination disparity drug EHR Emergency use authorization EUA facilitate food Health help high risk highest Hispanic patient Immunocompromised less mAb medication Mild-to-moderate molnupiravir monoclonal antibody Native outcomes Outpatient Patient patient groups patients Paxlovid PROTECT Racial Remdesivir report risk seeking severe COVID-19 treated Treatment United States were used White patients [DOI] 10.15585/mmwr.mm7143a2 PMC 바로가기
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant RecipientsArticle Published on 2022-10-192022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] administration analyzed booster booster dose booster doses Breakthrough infection cellular response CLIA Cohort COVID-19 dose Efficacy ELISA ELISpot assay fourth dose General population humoral IgA IgA level IgG immune immune response IMPROVE in both group Infection mRNA mRNA vaccine natural natural infection new SARS-CoV-2 no difference Organ transplant Patient positive recipient recipients repeated response SARS-CoV-2 SARS-COV-2 infection secretion serum IgG severe COVID-19 significant increase significantly increased Solid solid organ transplant Solid organ transplant recipients Still T cell T-cell T-cell Response Transplant vaccination Vaccine vaccine-induced immune response variants of concern [DOI] 10.3390/v14102299 PMC 바로가기
Global Vaccine Inequality Threatens to Unleash the Next COVID-19 VariantMini review Published on 2022-10-012022-10-05 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] adopted B.1.1.529 B.1.617.2 booster doses country COVID-19 COVID-19 infection delta variant dominant Europe Healthcare disparity inequality lowest omicron pandemic persistence Prevent Region South Africa strain the United State The United States vaccination rate Vaccine vaccine availability Vaccines variant variants virus [DOI] 10.1016/j.ijid.2022.08.010 [Article Type] Mini review
Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents – 19 States, March 29-July 25, 2022Article Published on 2022-09-302022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] Against Analysis B.1.1.529 booster booster dose booster doses cause collected Committee Community COVID-19 COVID-19 infection COVID-19 vaccine death deaths dose Effectiveness Endpoint evaluated facility Follow-up home Hospitalization Immunocompromised monovalent vaccine morbidity and mortality mRNA Nursing omicron outcome outcomes Practice predominant Prevent provided resident routine care SARS-CoV-2 second severe COVID-19 vaccination Vaccine variant variants virus with COVID-19 [DOI] 10.15585/mmwr.mm7139a2 PMC 바로가기
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugsArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome adverse event antibody concentration axial spondyloarthritis biological disease-modifying drug BNT162b2 BNT162b2 vaccine booster booster doses booster vaccination clinical questionnaire Cohort cohorts comparable coronavirus disease Coronavirus-2 COVID-19 enrolled evaluated Evidence flow cytometric General population healthy control humoral IL-17 immune response Immune-mediated inflammatory disease immunogenicity individuals inhibitor inhibitors intracellular cytokine investigated male no difference outcome Patient patients patients treated peptide-based persistence prospective observational study Responder Safety SARS-CoV-2 Specific spondyloarthritis subgroups T-cell T-cell immune response T-cell Response therapy TNFα treated tumor necrosis factor-alpha vaccination virus-neutralizing antibody were assessed [DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기
Assessing COVID-19 vaccination strategies in varied demographics using an individual-based modelArticle Published on 2022-09-152022-11-15 Journal: Frontiers in Public Health [Category] SARS, 변종, 치료기술, 치료제, [키워드] age agent-based model (ABM) applied Assessing asymptomatic infections booster doses Characteristics Contact COVID COVID- 19 COVID-19 COVID-19 vaccination COVID-19 vaccine demographics distribution distributions Effectiveness Efficiency help Hospitalization household size individual individual-base model Infection infection rate Intervention New non-pharmaceutical interventions (NPIs) NPI NPIs outbreak parameter Prevent Probability reproductive responses against SARS-CoV-2 severe disease structures subpopulation symptomatic Total unique vaccinate vaccination Vaccination strategies Vaccination strategy variants variants of SARS-CoV-2 [DOI] 10.3389/fpubh.2022.966756 PMC 바로가기